Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes
- PMID: 20572310
- PMCID: PMC2890947
- DOI: 10.3748/wjg.v16.i24.3056
Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes
Abstract
Aim: To analyze the combined treatment of resection and intraoperative radiofrequency ablation (RFA) for multifocal hepatocellular carcinoma in terms of prognosis and surgical outcomes.
Methods: This study was a retrospective case comparison study using prospectively collected data. The study covered the period from April 2001 to December 2006. The data of 200 patients with histologically confirmed hepatocellular carcinoma were reviewed. Nineteen patients (17 men and 2 women) having received resection in combination with RFA were chosen as subjects of the study (the combination group). Fifty-four patients (43 men and 11 women) having received resection alone were selected for comparison (the resection group). The two groups matched tumor number and tumor size, and all the patients in the two groups displayed no tumor rupture, major vascular involvement and distant metastasis. Their demographics, preoperative assessment, disease recurrence patterns, overall survival and disease-free survival were compared.
Results: In the combination group, the median age was 65 years (range, 34-77 years), the median tumor number was 3 (range, 2-9), and the median tumor size was 6 cm (range, 1.2-14 cm). In the resection group, the median age was 51.5 years (range, 27-80 years, P = 0.003), the median tumor number was 3 (range, 2-9, P = 0.574), and the median tumor size was 6 cm (range, 1-14 cm, P = 0.782). The two groups were similar in characteristics of tumors and comorbidities, and had comparable results in preoperative liver function tests. All patients had Child-Pugh class A status. Bilobar involvement occurred in 14 patients (73.6%) in the combination group and 3 patients (5.5%) in the resection group (P = 0.04). Six patients (32%) in the combination group and 35 patients (65%) in the resection group underwent major hepatectomy. Thirteen patients (68%) in the combination group and 19 patients (35%) in the resection group underwent minor hepatectomy (P = 0.012). The combination group had fewer major resections (32% vs 65%, P = 0.012), less blood loss (400 vs 657 mL, P = 0.007), shorter operation time (270 vs 400 min, P = 0.001), and shorter hospital stay (7 vs 8.5 d, P = 0.042). The two groups displayed no major differences in surgical complications (15.8% vs 31.5%, P = 0.24), disease recurrence (63.2% vs 50%, P = 0.673), hospital mortality (5.3% vs 5.6%, P = 1), and overall survival (53 vs 44.5 mo, P = 0.496).
Conclusion: Safe and effective for selected patients with multifocal hepatocellular carcinoma, the combination of resection and intraoperative RFA widens the applicability of surgical intervention for the disease.
Figures
Similar articles
-
Minimally invasive surgery versus radiofrequency ablation for single subcapsular hepatocellular carcinoma ≤ 2 cm with compensated liver cirrhosis.Surg Endosc. 2020 Dec;34(12):5566-5573. doi: 10.1007/s00464-019-07357-x. Epub 2020 Jan 28. Surg Endosc. 2020. PMID: 31993821
-
Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule <2 cm): a single-center study.Eur J Gastroenterol Hepatol. 2014 Mar;26(3):339-44. doi: 10.1097/MEG.0000000000000012. Eur J Gastroenterol Hepatol. 2014. PMID: 24150522 Clinical Trial.
-
Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.Eur Radiol. 2019 May;29(5):2679-2689. doi: 10.1007/s00330-018-5902-4. Epub 2018 Dec 17. Eur Radiol. 2019. PMID: 30560364
-
Impact of tumor size on the outcomes of hepatic resection for hepatocellular carcinoma: a retrospective study.BMC Surg. 2024 Jan 3;24(1):7. doi: 10.1186/s12893-023-02296-w. BMC Surg. 2024. PMID: 38172802 Free PMC article. Review.
-
Outcomes of liver resection for huge hepatocellular carcinoma exceeding 10 cm in size: A single center experience.Am J Surg. 2023 Jun;225(6):1013-1021. doi: 10.1016/j.amjsurg.2022.12.005. Epub 2022 Dec 7. Am J Surg. 2023. PMID: 36517275 Review.
Cited by
-
Current Perspectives of Immunotherapy for Hepatocellular Carcinoma.Comb Chem High Throughput Screen. 2025;28(2):185-201. doi: 10.2174/0113862073255266231025111125. Comb Chem High Throughput Screen. 2025. PMID: 38031784 Review.
-
A systematic review and meta-analysis of radio frequency ablation and routine resection in the treatment of small hepatocellular carcinoma.J Gastrointest Oncol. 2021 Apr;12(2):770-780. doi: 10.21037/jgo-21-52. J Gastrointest Oncol. 2021. PMID: 34012665 Free PMC article.
-
Hepatic Resection Is Associated With Improved Long-Term Survival Compared to Radio-Frequency Ablation in Patients With Multifocal Hepatocellular Carcinoma.Front Oncol. 2020 Feb 11;10:110. doi: 10.3389/fonc.2020.00110. eCollection 2020. Front Oncol. 2020. PMID: 32117759 Free PMC article.
-
The role of intraoperative ultrasonography in the diagnosis and management of focal hepatic lesions.Ultrasonography. 2015 Oct;34(4):246-57. doi: 10.14366/usg.15014. Epub 2015 Apr 6. Ultrasonography. 2015. PMID: 25971896 Free PMC article. Review.
-
Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma.J Cancer Res Clin Oncol. 2018 Feb;144(2):205-214. doi: 10.1007/s00432-017-2543-y. Epub 2017 Nov 10. J Cancer Res Clin Oncol. 2018. PMID: 29127494 Free PMC article.
References
-
- Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225–235. - PubMed
-
- Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381–388. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous